Apogee Therapeutics Inc. (NASDAQ: APGE) reported that Chief Financial Officer Jane Henderson sold 2,000 shares of the company's common stock on April 16, 2026, at $90.00 per share, producing $180,000 in gross proceeds.
The disposition was carried out under a Rule 10b5-1 trading plan that Henderson adopted on September 2, 2025. Following this sale, Henderson directly holds 175,371 shares of Apogee Therapeutics.
Apogee's share price has risen sharply over the last year, delivering approximately a 178% gain and trading near a 52-week high of $95.31. Independent valuation commentary cited in company-related analysis describes the stock as appearing overvalued at current levels, a point investors may wish to weigh alongside other developments.
Recent capital markets activity
Alongside the insider sale, Apogee completed an underwritten public offering that raised about $403 million in gross proceeds. That offering included the full exercise of the underwriters' option to purchase an additional 750,000 shares, with the shares in that transaction priced at $70.00 each. After underwriting discounts and other offering-related expenses, the company expects net proceeds of roughly $377.4 million.
Separately, Apogee announced that it has priced another public offering, projected to generate gross proceeds of $350 million. Management has presented these financings as part of the company's recent financing strategy.
Analyst notes and data updates
Following presentation of 52-week APEX Part A results, BTIG reiterated a Buy rating on Apogee with a $137 price target. Mizuho also raised its price target to $110 from $105 and kept an Outperform rating after reviewing data related to zumilokibart in atopic dermatitis. Mizuho’s decision to lift the target reflected a 10% increase in its assessed probability of success for that indication, according to the company disclosures.
What this collection of actions means
The combination of an insider sale under a pre-arranged trading plan, large public offerings, and positive analyst updates represents a concentrated period of financial and market activity for Apogee. Investors tracking insider transactions, dilution and analyst viewpoints will likely view these items together when assessing the stock’s near-term positioning.
Note: The article presents transaction, offering and analyst detail as disclosed by the company and related filings.